Key Takeaways FILSPARI's expanding use and recognition in rare kidney diseases positions Travere for first-mover advantage, sustained growth, and meaningful gains in underserved markets. Strong financial discipline, increasing recurring revenue, and efficient regulatory progress provide resources for pipeline advancement and future commercial launches.Read more
Key Takeaways Rapid market adoption, limited competition, and clinical leadership uniquely position Travere to achieve dominance and pricing power in rare kidney disease therapies. Strong operational execution and favorable industry trends support robust revenue growth, superior margins, and a resilient, cash-generative business model.Read more
Key Takeaways Heavy reliance on FILSPARI and persistent net losses create vulnerability to competition, regulatory changes, and setbacks in new product development. Increasing R&D expenses and pricing pressures from government controls threaten margins, limiting sustainable growth and financial flexibility despite favorable market trends.Read more
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
